STRATEGIC COLLABORATIONS & PARTNERSHIPS

 

Advancing the Next Generation of Bacterial Vaccines

 

Together TurboVax believes that the fastest path to improving global health is through strategic partnerships with organizations that share our commitment to vaccine innovation.

 

Rather than building a fully integrated vaccine manufacturing company, TurboVax is developing a proprietary immunological platform designed to complement and strengthen existing bacterial glycoconjugate vaccine programs.

 

​​

​

​

​

Partnership Opportunities

 

Vaccine Manufacturers

 

Integrate the Turbo platform into licensed and next-generation glycoconjugate vaccine programs to improve durability, consistency, and long-term protective immunity.

​​​

​

Biotechnology Companies

 

Collaborate to develop innovative bacterial vaccine candidates incorporating defined innate immune costimulation.

​

​​​

Government & Non-Profit Organizations

 

Partner with TurboVax to accelerate the development of vaccines addressing unmet public health needs through non-dilutive funding and collaborative research.

​​​

​​

Academic Institutions

​​

Collaborate on mechanistic immunology, translational vaccine research, and next-generation glycoconjugate vaccine development.

​​

​

​

​

 

Why Partner with TurboVax?

 

Scientifically Validated

​

A mechanistically defined platform supported by peer-reviewed publications

and extensive immunological research.​

​

 

Platform Technology

 

Designed to integrate with multiple bacterial glycoconjugate vaccine programs.

​​

​

Strong Intellectual Property

​

Proprietary technology protected through an expanding intellectual property portfolio.

 

​​​

Experienced Leadership

 

Supported by internationally recognized scientific, clinical,

regulatory and business advisors.

 

​​

​

​

Our Partnership Philosophy

​

TurboVax believes that transformative vaccine innovation is best achieved through collaboration.

 

Our goal is to work alongside pharmaceutical companies, biotechnology innovators, academic investigators, and public health organizations to accelerate the translation of fundamental immunology into vaccines that improve human health worldwide.

 

​​

​

​

Let's Build the Next Generation of Bacterial Vaccines Together

 

If your organization is interested in strategic partnerships, licensing opportunities, collaborative research, or investment discussions, we would welcome the opportunity to connect.

 

Kishore R. Alugupalli, PhD

Founder & Chief Executive Officer, TurboVax Inc.

​

Email: kra@turbovaxinc.com

Phone: +1 856 283 1125

LinkedIn: https://www.linkedin.com/in/kishore-alugupalli-44559286/

Website: www.turbovaxinc.com